Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

New Insights from Pharmidex: Tumour Microdialysis in Glioblastoma
July 10, 2025
We’re excited to share our latest work on tumour microdialysis, a powerful technique for measuring unbound, pharmacologically active drug concentrations directly within brain tumours like glioblastoma. Unlike systemic plasma levels, microdialysis provides a true picture of drug penetration into the tumour helping to uncover heterogeneous distribution and the impact of the blood-tumour barrier. Our approach involves precise stereotaxic surgery, tumour validation, and sampling from both tumour and healthy brain tissue enabling direct, comparative pharmacokinetic analysis. 📊 The results? Significant differences in drug exposure between tumour core and surrounding tissue. 👉 Swipe through the carousel to explore our process and findings.  🔗 www.pharmidex.com
Pharmidex at ON Helix 2025
July 2, 2025
We’re excited that Ash Alavijeh (Head of Operations) and Ian Knowles (Head of Respiratory) will attend ON Helix 2025 on 3 July in Cambridge, UK .  They look forward to meeting fellow attendees and exploring new ways to collaborate in drug discovery and development . 📍 https://www.onhelix.com
Milner Therapeutics Symposium 2025
June 30, 2025
We’re excited that Ash Alavijeh (Head of Operations) and Janette Robertson (Business Development Manager) will attend the Milner Therapeutics Symposium on 30 June 2025 in Cambridge.  They look forward to connecting with attendees and discussing how Pharmidex can support collaboration and innovation in drug discovery. 📍 https://milner.glueup.com/event/milner-therapeutics-symposium-2025-132179/home.html
More Posts